

Lawrence Berkeley National Laboratory

LBL Publications

Title

Antagonism between substitutions in β -lactamase explains a path not taken in the evolution of bacterial drug resistance Epistasis between resistance mutations in β -lactamase

Permalink

<https://escholarship.org/uc/item/7mm439vv>

Journal

Journal of Biological Chemistry, 295(21)

ISSN

0021-9258

Authors

Brown, Cameron A

Hu, Liya

Sun, Zhizeng

et al.

Publication Date

2020-05-01

DOI

10.1074/jbc.ra119.012489

Peer reviewed



Antagonism between substitutions in β -lactamase explains a path not taken in the evolution of bacterial drug resistance

Received for publication, December 28, 2019, and in revised form, April 14, 2020. Published, Papers in Press, April 16, 2020, DOI 10.1074/jbc.RA119.012489

Cameron A. Brown⁺¹, Liya Hu^S, Zhizeng Sun[‡], Meha P. Patel[‡], Sukrit Singh[¶], Justin R. Porter[¶], Banumathi Sankaran^{||}, B. V. Venkataram Prasad^S, Gregory R. Bowman[¶], and Timothy Palzkill^{‡S2}

From the [‡]Department of Pharmacology and Chemical Biology and the ^SVerna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, the ^{||}Department of Molecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology, Lawrence Berkeley National Laboratory, Berkeley, California 94720, and the [¶]Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri 63110

Edited by Chris Whitfield

CTX-M β -lactamases are widespread in Gram-negative bacterial pathogens and provide resistance to the cephalosporin cefotaxime but not to the related antibiotic ceftazidime. Nevertheless, variants have emerged that confer resistance to ceftazidime. Two natural mutations, causing P167S and D240G substitutions in the CTX-M enzyme, result in 10-fold increased hydrolysis of ceftazidime. Although the combination of these mutations would be predicted to increase ceftazidime hydrolysis further, the P167S/D240G combination has not been observed in a naturally occurring CTX-M variant. Here, using recombinantly expressed enzymes, minimum inhibitory concentration measurements, steady-state enzyme kinetics, and X-ray crystallography, we show that the P167S/D240G double mutant enzyme exhibits decreased ceftazidime hydrolysis, lower thermostability, and decreased protein expression levels compared with each of the single mutants, indicating negative epistasis. X-ray structures of mutant enzymes with covalently trapped ceftazidime suggested that a change of an active-site Ω -loop to an open conformation accommodates ceftazidime leading to enhanced catalysis. 10- μ s molecular dynamics simulations further correlated Ω -loop opening with catalytic activity. We observed that the WT and P167S/D240G variant with acylated ceftazidime both favor a closed conformation not conducive for catalysis. In contrast, the single substitutions dramatically increased the probability of open conformations. We conclude that the antagonism is due to restricting the conformation of the Ω -loop. These results reveal the importance of conformational heterogeneity of active-site loops in controlling catalytic activity and directing evolutionary trajectories.

Enzymes have evolved to catalyze reactions critical to the functioning of the cell (1). Evolution of enzyme function proceeds through the accumulation of amino acid substitutions that shape stability, solubility, and catalytic activity, among other properties. How substitutions interact when combined plays a key role in the trajectory of mutations that accumulate during evolution (2, 3). For example, amino acid substitutions can act additively on catalysis whereupon each substitution increases activity, and upon combination, the increase in activity in the double mutant is the product of the fold changes of the individual mutations (4). Alternatively, combinations of substitutions are often nonadditive where the double mutant has a greater activity or less activity than expected based on the activity of the single mutants. Such nonadditive effects are termed epistasis and can strongly influence the mutational pathways that are possible in the evolution of enzyme function (5, 6).

Enzymes act by binding substrates and stabilizing transition states of reactions (1). Toward this end, conformational changes are often important, and flexible loops in the active site are a common feature involved in enzyme function (7–9). Moreover, conformational dynamics have been proposed to play an important role in protein evolvability (10, 11). By this view, conformational fluctuations can result in an enzyme adopting multiple structures, some of which have properties that allow interactions with alternate ligands. These conformations may be rare in the ensemble of WT structures, but mutations may shift the distribution toward alternate conformations that become dominant in an evolved enzyme, thereby allowing for altered substrate specificity or new enzyme functions to emerge on an enzyme scaffold (11, 12).

Here, we address the role of epistasis and conformational diversity of active-site loops in the evolution of variants of the CTX-M β -lactamase with a broadened substrate specificity for β -lactam antibiotics. β -Lactams are the most frequently prescribed class of antibiotic worldwide, making up 65% of all use (13). However, bacterial resistance to these drugs is a growing problem, and the most common mechanism of resistance is enzyme-mediated hydrolysis of the β -lactam ring (14). This hydrolysis is catalyzed by various β -lactamases, which are divided into classes A–D based on primary amino acid sequence homology (14, 15).

Class A β -lactamases, such as CTX-M, are widespread in Gram-negative bacteria and share a similar mechanism of

This work was supported by National Institutes of Health Grants R01 AI32956 (to T. P.) and R01 GM12400701 (to G. R. B.) and by Robert Welch Foundation Grant Q1279 (to B. V. V. P.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This article contains Table S1 and Figs. S1–S3.

The atomic coordinates and structure factors (codes 6V5E, 6V6G, 6V6P, 6V7T, 6V8V, and 6V83) have been deposited in the Protein Data Bank (<http://www.pdb.org/>).

¹ Supported by National Institutes of Health Training Grant T32 GM120011.

² To whom correspondence should be addressed: One Baylor Plaza, Houston, TX 77030. Tel.: 713-798-5609; E-mail: timothy.palzkill@bcm.edu.




Figure 1. β -Lactamase mechanism. *A*, reaction scheme for β -lactamase where *E* represents β -lactamase, *ES* represents the enzyme-substrate complex, *EAc* represents the acyl-enzyme complex, and *P* represents product. k_1 and k_{-1} are the rate constants for association and dissociation of the enzyme-substrate complex, and k_2 and k_3 are the rate constants for acylation and deacylation, respectively. *B*, schematic illustration of β -lactamase mechanism. The catalytic Ser⁷⁰ hydroxyl group is activated for nucleophilic attack on the carbonyl oxygen of the amide bond of the β -lactam by an active-site residue serving as a general base. This residue is viewed as either Lys⁷³ or Glu¹⁶⁶ acting through a water molecule. This leads to formation of the acyl-enzyme intermediate, which is subsequently deacylated by a water that is activated by Glu¹⁶⁶ acting as a base and resulting in free enzyme and the hydrolyzed product.

catalysis but can differ widely in substrate profile (16, 17). These enzymes are serine hydrolases that hydrolyze the amide bond in the β -lactam ring via sequential acylation and deacylation steps. The conserved catalytic Ser⁷⁰ residue is activated by Lys⁷³ and Glu¹⁶⁶ for attack on the carbonyl carbon to form an acyl-enzyme intermediate. A catalytic water molecule is then activated by Glu¹⁶⁶ for attack on the carbonyl of the covalent complex to deacylate the enzyme and release the product (Fig. 1) (17–19). The reaction scheme and mechanism of serine β -lactamases is shown in Fig. 1.

CTX-M β -lactamases are a family of class A extended-spectrum β -lactamases that are so named because they efficiently hydrolyze the oxyimino-cephalosporin cefotaxime (20) (Fig. 2). To date, more than 140 variants of the CTX-M enzymes have been identified (21). CTX-M-14 β -lactamase has become a model system for studies of the structure and function of CTX-M enzymes (22–25).

CTX-M enzymes efficiently hydrolyze cefotaxime but not another commonly used oxyimino-cephalosporin, ceftazidime (Fig. 2A). Natural variants containing either the P167S or D240G substitutions have emerged, however, that more efficiently hydrolyze ceftazidime (21, 26–28). These two substitutions, when present, individually increase k_{cat}/K_m for ceftazidime hydrolysis by 10-fold, resulting in increased ceftazidime resistance for bacteria containing the mutants (22, 25). Multiple natural variants in the CTX-M family possess one of these substitutions (21).

Pro¹⁶⁷ resides in the Ω -loop that forms the bottom of the active site in class A β -lactamases including CTX-M enzymes (22, 29) (Fig. 2D). It is adjacent to Glu¹⁶⁶, which is conserved and serves as a general base to activate a water molecule for deacylation of β -lactam substrates (29). The peptide bond preceding Pro¹⁶⁷ is in a *cis* conformation in CTX-M enzymes,

which strongly influences the conformation of the Ω -loop and the positioning of the Asn¹⁷⁰ residue that hydrogen bonds to Glu¹⁶⁶ and the deacylation water. We previously used the CTX-M-14 enzyme as a model system to examine the structural changes caused by the P167S substitution (25). These studies revealed a large conformational change of the Ω -loop that results in a larger active-site cavity to accommodate ceftazidime. This conformational change required both the P167S substitution and the presence of acylated ceftazidime (25). In addition, the structures showed that the conformational change is associated with a shift in the peptide bond preceding residue 167 from *cis* to *trans* and that the P167S substitution was required for this shift. Thus, the P167S substitution appears to cause increased ceftazidime hydrolysis through promoting a conformational change to relieve steric restraints on catalysis.

Chen *et al.* (22) previously determined the X-ray structure of the D240G mutant enzyme, and anisotropic B-factor analysis revealed increased flexibility of the B3 β -strand that forms one side of the CTX-M active site. The increased flexibility of the B3 β -strand was proposed to allow access for the bulky side chain of ceftazidime.

Despite the increase in ceftazidime hydrolysis and bacterial resistance resulting from each of the substitutions, there has yet to be a CTX-M enzyme identified in clinical isolates that harbors both the P167S and D240G mutations. Based on simple additivity, the combination of substitutions that each increase hydrolysis by 10-fold would be expected to increase hydrolysis 100-fold relative to the WT enzyme (4). However, a P167S/D240G double mutant created by site-directed mutagenesis in a CTX-M-3 enzyme background exhibited a loss of ceftazidime resistance, indicating an antagonist effect and negative epistasis (30). The mechanism of this antagonism, however, was not examined.

Here, we show that the P167S/D240G double mutant displays decreased ceftazidime hydrolysis compared with either of the single mutants, indicating antagonism. Further, X-ray structures of single and double mutants as apoenzymes and acylated with ceftazidime show alternate open and closed conformations of the Ω -loop that are associated with high and low activity. Finally, molecular dynamics simulations of the WT, P167S, D240G, and P167S/D240G enzymes acylated with ceftazidime indicate that the single substitutions dramatically increase the probability of open conformations of the Ω -loop, whereas the WT and P167S/D240G variant both favor a well-defined closed conformation not favorable for catalysis. Taken together, the results suggest that the P167S/D240G double mutant has not been observed in resistant clinical isolates because the combination results in decreased catalysis, decreased stability, and therefore decreased fitness in the presence of ceftazidime for bacteria containing this enzyme.

Results

Ceftazidime resistance levels of P167S/D240G double mutant are reduced compared with single mutants

The P167S and D240G substitutions have been observed in multiple CTX-M β -lactamase variants and are associated with 10-fold increased ceftazidime hydrolysis (22, 24). Further,

Epistasis between resistance mutations in β -lactamase




Figure 2. Structures of antibiotics and CTX-M-14 β -lactamase. A, cephalothin. R1 and R2 denote the groups that differ between cephalosporins. B, cefotaxime. C, ceftazidime. D, structure of CTX-M-14 β -lactamase (PDB code 1YLT). The Ω -loop is colored green. The catalytic Ser⁷⁰ is colored orange. Pro¹⁶⁷ and Asp²⁴⁰ are colored gray. Note that Pro¹⁶⁷ is located on the Ω -loop.

introduction of the P167S and D240G substitutions into the CTX-M-3 β -lactamase results in lower ceftazidime resistance than either of the single mutants (30). We extended these findings to the CTX-M-14 model system by determining minimum inhibitory concentrations (MICs)³ for ceftazidime, cefotaxime, and cephalothin for *Escherichia coli* harboring WT and the mutants (Table 1). The results show that the P167S and D240G individual substitutions both result in increased resistance to ceftazidime, whereas the P167S/D240G double mutant exhibits a loss of ceftazidime resistance compared with either the P167S or D240G single mutants (Table 1) (24, 30). These data confirm the apparent incompatibility of the P167S and D240G substitutions as first suggested by Novais *et al.* (30) and extends the findings to the CTX-M-14 enzyme background.

Antibiotic hydrolysis by the P167S/D240G double mutant is reduced compared with single mutants

Although the P167S and D240G substitutions increase the catalytic efficiency (k_{cat}/K_m) for ceftazidime hydrolysis by \sim 10-fold, the activity of the P167S/D240G double mutant enzyme has not been examined (24, 26, 27, 31). Therefore, both WT and the double mutant CTX-M-14 enzymes were purified, and their kinetic parameters were determined for hydrolysis of the oximino-cephalosporins cefotaxime and ceftazidime, as well as cephalothin (Table 2).

Ceftazidime hydrolysis by the WT, P167S, and D240G enzymes exhibits high K_m values ($>500 \mu\text{M}$), which precluded determination of k_{cat} values (24). Nevertheless, k_{cat}/K_m values for the P167S and D240G enzymes were 10-fold higher than that observed for WT CTX-M-14. If the P167S and D240G substitutions act additively, k_{cat}/K_m for ceftazidime by the dou-

Table 1

MICs for *E. coli* containing CTX-M-14 wild type, mutants, and no β -lactamase control

WT or mutant β -lactamase	MIC		
	Cephalothin	Cefotaxime	Ceftazidime
		$\mu\text{g/ml}$	
pTP123	12	0.0625	0.19
CTX-M-14 wt	>256	1.5	0.75
P167S	>256	0.375	12
D240G	>256	1	1.5
P167S/D240G	>256	0.19	0.75

ble mutant should be a further 10-fold higher than that observed for the single mutants (4). However, k_{cat}/K_m for ceftazidime hydrolysis by the double mutant was \sim 2-fold lower than that observed for the P167S and D240G single mutants (Table 2). Therefore, the P167S and D240G substitutions are antagonistic with respect to ceftazidime hydrolysis. This suggests that the presence of one substitution alters the environment of the other to perturb its contribution to catalysis (4).

The P167S and D240G substitutions were previously observed to modestly increase k_{cat}/K_m for cefotaxime hydrolysis (\sim 2-fold) compared with the WT enzyme (24). The P167S/D240G double mutant exhibited a k_{cat}/K_m value similar to WT and 2-fold lower than the single mutants indicating possible antagonism, as found for ceftazidime hydrolysis (Table 2).

The second-generation cephalosporin cephalothin is an excellent substrate for the WT CTX-M-14 enzyme (Table 2) (24). The P167S and D240G substitutions reduce both k_{cat} and K_m values for cephalothin hydrolysis (Table 2). The P167S/D240G double mutant exhibited a further reduction in k_{cat} and K_m compared with the single mutants. Interestingly, the P167S and D240G substitutions act additively in the double mutant for cephalothin hydrolysis. Therefore, the additivity relationship between the P167S and D240G substitutions is substrate-dependent, with simple additivity observed for cephalothin and antagonism observed for ceftazidime hydrolysis, suggesting

¹ The abbreviations used are: MIC, minimum inhibitory concentration; PDB, Protein Data Bank; ESBL, extended-spectrum β -lactamase; CMP, chloramphenicol; IPTG, isopropyl- β -D-galactopyranoside; MBP, maltose-binding protein.

Table 2
Enzyme kinetic parameters of CTX-M-14 β -lactamase and mutant enzymes

Enzyme	Parameter	Cephalothin	Cefotaxime	Ceftazidime
CTX-M-14	k_{cat} (s^{-1})	1400 \pm 38	161 \pm 9	ND ^a
	K_m (μM)	83 \pm 6	60 \pm 7	>500
P167S ^b	k_{cat}/K_m ($\mu\text{M}^{-1}\text{s}^{-1}$)	17.0 \pm 0.7	2.71 \pm 0.16	0.0011 \pm 0.00007
	k_{cat} (s^{-1})	681 \pm 36.8	297 \pm 29.7	ND
	K_m (μM)	32 \pm 0.8	37 \pm 6.3	>500
D240G ^b	k_{cat}/K_m ($\mu\text{M}^{-1}\text{s}^{-1}$)	21.1 \pm 1.3	8.0 \pm 1.6	0.011 \pm 0.0002
	k_{cat} (s^{-1})	471 \pm 10.9	321 \pm 46.2	ND
	K_m (μM)	47.1 \pm 41.7	52 \pm 8.6	>500
P167S/D240G	k_{cat}/K_m ($\mu\text{M}^{-1}\text{s}^{-1}$)	10.0 \pm 2.5	6.2 \pm 1.4	0.013 \pm 0.0007
	k_{cat} (s^{-1})	165 \pm 11	139 \pm 3	ND
	K_m (μM)	15 \pm 3	42 \pm 0.5	>500
	k_{cat}/K_m ($\mu\text{M}^{-1}\text{s}^{-1}$)	10.8 \pm 1.4	3.27 \pm 0.1	0.0060 \pm 0.00004

^a ND, not determined.^b Kinetic parameters for P167S and D240G mutant enzymes from Patel *et al.* (24).


that the effects are mediated through interaction with the substrates.

P167S/D240G double mutant exhibits reduced stability compared with single mutants

Amino acid substitutions can affect catalysis, as shown above, but also can impact protein stability. It was previously shown that the P167S and D240G single mutants destabilize CTX-M-14 (24). We extended this finding to the P167S/D240G enzyme using CD spectroscopy to monitor α -helix ellipticity with increasing temperature (Fig. 3). Previous studies showed that the WT CTX-M-14 exhibited a melting temperature (T_m) of 54.6 °C, and the single mutants D240G and P167S decreased the T_m by 0.4 and 2.8 °C, respectively (24). The P167S/D240G enzyme exhibited a T_m of 50.5 °C, indicating that the double mutant is less stable than WT and the single mutants (Fig. 3).

Steady-state levels of the P167S/D240G enzyme in *E. coli* are reduced compared with single mutants

The level of antibiotic resistance conferred to bacteria by a β -lactamase depends on the rate of hydrolysis, as well as the steady-state levels of enzyme expression (32). A correlation has been shown between β -lactamase stability and expression levels in *E. coli* caused by increased proteolysis and aggregation of unstable proteins (32–34). Because the P167S and D240G substitutions decrease enzyme stability and the double mutant decreases stability further, we hypothesized that the double mutant would display lower expression levels. Immunoblot analysis of whole cell lysates using α -CTX-M-14 β -lactamase polyclonal antibody showed that the P167S mutant did not significantly decrease expression levels relative to WT, consistent with previous studies (Fig. 4) (24). The D240G mutant, which shows only a 0.4 °C decrease in stability relative to WT, displayed lower expression levels. Thus, although D240G has higher thermal stability than P167S, it displays lower expression levels, indicating that thermal stability does not fully correlate with expression levels. However, the P167S/D240G enzyme exhibited lower expression levels than either WT or the P167S and D240G single mutants, consistent with the lower thermal stability of this mutant. Taken together, these findings provide a rationale for why the P167S/D240G double mutant has not been observed in resistant clinical isolates in that it is compromised for catalysis, stability, and expression levels compared with the P167S and D240G single mutants.



Thermal stabilities of CTX-M variants

WT or mutant β -lactamase	T_m (°C)	ΔT_m (°C)
CTX-M-14	54.0 \pm 0.09	-
D240G	53.6 \pm 0.08	-0.4
P167S	51.8 \pm 0.16	-2.2
P167S:D240G	50.5 \pm 0.56	-3.5

Figure 3. Thermal stability of WT and mutant β -lactamases, as measured by CD. Mean ellipticity is normalized and fit to a Boltzmann sigmoidal function. T_m , as determined by the Boltzmann equation, is also plotted, as is ΔT_m , which is the change from the WT T_m . The T_m indicates that each single mutant is less stable than the WT CTX-M-14 enzyme, and this instability has an additive effect in the double mutant, P167S/D240G CTX-M-14. The data for CTX-M-14, D240G, and P167S are from Patel *et al.* (24).

X-ray structures of P167S/D240G apo, E166A/D240G/CAZ, and E166A/P167S/D240G/CAZ acyl-enzyme complexes reveal alternate conformations of the Ω -loop

We previously determined the X-ray structure of the P167S enzyme, which had a very similar overall structure as WT (25). The Ω -loop, which forms the bottom of the active site, was in a folded, closed conformation with the peptide bond preceding Ser¹⁶⁷ in a *cis* configuration (Fig. 5, A–C). The structure of the D240G enzyme was previously determined, and it also is highly similar to the WT structure (22) (Fig. 5D). We next determined the structure of the P167S/D240G enzyme, which exhibits lower ceftazidime hydrolysis than either of the single mutants. The structure includes a boronic acid from the crystallization buffer in complex with Ser⁷⁰ and is very similar to the WT, P167S, and D240G structures, with the Ser¹⁶⁷ peptide bond in the *cis* configuration and the Ω -loop in a folded, closed conformation (Fig. 5, E–H, and Table S1). A difference was noted, however, in the B-factors in the active-site 103–106 loop, suggesting increased disorder. B-factors reflect the degree to which electron density is scattered and therefore indicate how ordered an atom is in the structure (35). The B-factors for resi-

Epistasis between resistance mutations in β -lactamase




Figure 4. Steady-state protein levels of WT CTX-M-14 and mutant β -lactamases. Western blotting analysis with an anti-CTX-M-14 polyclonal antibody shows protein expression levels of WT CTX-M-14 and the P167S, D240G, and P167S/D240G mutants in the periplasm of recombinant *E. coli* cells. Analysis with a polyclonal antibody to the periplasmic protein MBP was used as a loading control. The hybridization signal was visualized by chemiluminescence and quantified by densitometry. The signal for CTX-M-14 β -lactamase was normalized to that for MBP in the same sample. The protein levels of mutant CTX-M-14 β -lactamase are expressed relative to that of WT CTX-M-14 β -lactamase in the bar graph. The quantification data in the bar graph are the averages of two independent experiments, and one representative immunoblot result is shown above the bar graph.

dues in the 103–106 loop and the 164–179 Ω -loop were normalized to the overall B-factor of each structure to facilitate comparison across structures (Fig. 6). The normalized B-factors for the P167S/D240G structure for residues Val¹⁰³ and Asn¹⁰⁴ were higher than in the WT, P167S, and D240G structures. These findings suggest increased disorder for residues 103–104 in the P167S/D240G structure. We have previously shown that Asn¹⁰⁴ is important for cefotaxime and ceftazidime hydrolysis, and therefore increased disorder of this residue in the P167S/D240G enzyme could result in the observed lower activity for ceftazidime hydrolysis (36).

We next determined the structures of the mutant enzymes in complex with ceftazidime to evaluate whether the presence of substrate influences active-site structure (Table S1). The E166A mutation blocks deacylation and allows for crystallization of the acyl-enzyme complex (29). The previously determined structure of the acyl-enzyme complex of the CTX-M-14 pseudo WT E166A enzyme with ceftazidime (E166A/CAZ) shows the Pro¹⁶⁷ peptide bond in the *cis* configuration and the Ω -loop in the folded, closed conformation (Fig. 7A) (25). Contacts between ceftazidime and the enzyme include hydrogen bonds between the side chains of Asn¹³² and Asn¹⁰⁴ with the carbonyl oxygen of the acylamide of the ceftazidime R-2 group, as well as hydrogen bonds between the hydroxyls of Thr²³⁵ and Ser²³⁷ with the C4 carboxylate of the dihydrothiazine ring (Figs. 2C and 7A). The imino group of ceftazidime is pointed to solvent and does not interact with the enzyme. The previously determined structure of E166A/P167S/CAZ (Fig. 7B) shows the Ser¹⁶⁷ peptide bond in the *trans* configuration and the Ω -loop

in an unraveled, open conformation, which widens the floor of the active site by ~ 5 Å to accommodate ceftazidime (25). This leads to a change in conformation of ceftazidime in the acyl-enzyme with the aminothiazole ring assuming a buried position (Fig. 7B) (25). In addition, there are hydrogen bonds between the C4 carboxylate of the dihydrothiazine ring and the side chains of Thr²³⁵ and Ser²³⁷, as well as between the side chains of Asn¹³² and Asn¹⁰⁴ with the carbonyl oxygen of the acylamide group (Fig. 7B). Further, there is a hydrogen bond between Asn¹⁰⁴ and the carboxyl group of the imino side chain of ceftazidime. These interactions are consistent with tighter binding of ceftazidime and enhanced catalysis (25). In addition, the normalized B-factors of Val¹⁰³ and Asn¹⁰⁴ are not increased relative to WT CTX-M-14, suggesting that the Asn¹⁰⁴ residue is well-ordered for interaction with ceftazidime (Fig. 6A). Residues 168–170, however, show elevated B-factors, suggesting that the Ω -loop has increased flexibility, consistent with its unfolded structure (Fig. 6B).

The D240G substitution is also associated with increased ceftazidime hydrolysis (26, 28). We therefore determined the structure of the E166A/D240G enzyme in complex with ceftazidime for comparison with the E166A and E166A/P167S acyl-enzyme structures. It was found that the peptide bond preceding Pro¹⁶⁷ is in the *cis* configuration, and the Ω -loop is in the folded, closed conformation similar to the D240G apo enzyme structure and the E166A structure with ceftazidime (Fig. 7C). In contrast to the E166A/CAZ structure, however, the E166A/D240G/CAZ structure has the side chain of Ser²³⁷ rotated away from the C4 carboxylate and instead forms hydrogen bonds to the carboxylate of the imino side chain, which may facilitate substrate binding and catalysis (Figs. 2C and 7C).

The P167S/D240G enzyme displays lower catalytic activity toward ceftazidime than either single mutant (Table 2). To better understand the basis of this antagonism, we determined the structure of the E166A/P167S/D240G enzyme in complex with ceftazidime. Two structures from different space groups were obtained, and interestingly, they show different conformations of ceftazidime and the Ω -loop. In the first structure, the peptide bond preceding Ser¹⁶⁷ is in the *trans* configuration, which is in contrast to the *cis* bond found in the P167S/D240G apo structure (Fig. 5, D and E). However, the Ω -loop in the E166A/P167S/D240G/CAZ-1 structure remains in the folded, closed conformation with ceftazidime located in a similar position as that in the E166A/D240G/CAZ structure (Fig. 7D). There are differences, however, between these structures. First, the carboxylate group of the imino side chain of ceftazidime in the E166A/P167S/D240G/CAZ-1 structure does not contact the enzyme, in contrast to the E166A/D240G/CAZ structure (Fig. 7, C and D). More importantly, the positioning of the active-site 103–106 loop is altered, and the side chain of Asn¹⁰⁴ is shifted out of the active site in the E166A/P167S/D240G/CAZ-1 structure (Fig. 7D). In addition, the normalized B-factors for residues Val¹⁰³ and Asn¹⁰⁴ are elevated compared with the E166A/CAZ, E166A/P167S/CAZ, and E166A/D240G/CAZ structures, suggesting that Val¹⁰³ and Asn¹⁰⁴ are disordered (Fig. 6A). We have previously shown that the hydrogen bond between Asn¹⁰⁴ and the acyl-amide of cefotaxime and ceftazidime is important, and a N104A mutant exhibits 10-fold lower k_{cat}/K_m for both sub-




Figure 5. Structures of the active-site region of WT CTX-M14 β -lactamase (PDB code 1YLT), as well as P167S (PDB code 5TWD), D240G (PDB code 1YLP), and P167S/D240G mutant enzymes in the apo form. *A*, ribbon diagram showing structural alignment of the CTX-M-14 WT (salmon), P167S (gray), D240G (blue), and P167S/D240G (cyan) enzymes. The active-site region shown in *B–H* is boxed. *B–E*, active-site regions of CTX-M-14 WT (*B*), P167S (*C*), D240G (*D*), and P167S/D240G (*E*). Note that the P167S/D240G structure has a boronic acid in complex with Ser⁷⁰, which is not shown for clarity. *F*, structural alignment of active-site region of P167S apo enzyme (gray) with the P167S/D240G double mutant (cyan). *G*, structural alignment of D240G apo enzyme (blue) with P167S/D240G (cyan). *H*, structural alignment of CTX-M-14 WT apo enzyme with P167S/D240G (cyan). In all panels, oxygen is shown in red, and nitrogen is in blue.




Figure 6. Normalized B-factors for the 103–106 loop and the 164–179 Ω -loop in the CTX-M enzyme structures. The B-factors were normalized by dividing the B-factor for a given residue by the average B-factor for the entire structure. Thus, a normalized B-factor of 1 means the B-factor at that residue is the same as the average B-factor of the structure. *A*, normalized B-factors for the 103–106 loop. *B*, normalized B-factors for the 164–179 Ω -loop. Black circle, E166A/CAZ; blue square, E166A/P167S/CAZ; black triangle, E166A/D240G/CAZ; inverted red triangle, E166A/P167S/D240G/CAZ-1; green diamond, E166A/P167S/D240G/CAZ-2; open circle, P167S/D240G apo; open square, P167S apo; open triangle, D240G apo; inverted open triangle, E166A/P167S/D240G apo; open diamond, CTX-M-14 WT.

strates (36). These observations suggest that the conformation of the enzyme and ceftazidime observed in the E166A/P167S/D240G/CAZ-1 structure is not consistent with hydrolysis.

It is noteworthy that the E166A/P167S/D240G/CAZ-1 structure described above was obtained by soaking a crystal

with ceftazidime. Another crystal was also soaked, and the structure was determined with the same space group, but ceftazidime was not present in the active site. Interestingly, this apo structure is very similar to the structure with bound ceftazidime. The peptide bond preceding Ser¹⁶⁷ is in the *trans* con-

Epistasis between resistance mutations in β -lactamase




Figure 7. Structures of the active-site region of CTX-M-14 mutant β -lactamase acyl-enzyme complexes with ceftazidime. A, structure of the E166A mutant (*tan*) with ceftazidime (*dark gray*) trapped in the acyl-enzyme form (PDB code 5U53). Oxygen is shown in *red*, and nitrogen is in *blue*. Hydrogen bonds are indicated by *thin black lines*. Active-site residues are labeled. B, structure of the E166A/P167S/CAZ acyl-enzyme (*light blue*) (PDB code 5TW6). C, structure of the E166A/D240G/CAZ acyl-enzyme (*light green*). D, structure of the E166A/P167S/D240G/CAZ-1 acyl-enzyme (*pink*). E, structure of the E166A/P167S/D240G/CAZ-2 acyl-enzyme (*white*). F, structural alignment of the E166A/CAZ (*tan*) and E166A/D240G/CAZ (*green*) acyl-enzyme complexes. The ceftazidime from the E166A/CAZ structure is shown in *dark gray*, and that from E166A/D240G/CAZ is shown in *white*. The Ω -loop region remains folded in the closed form and the ceftazidime occupies a similar position with the aminothiazole ring surface exposed in these structures.

figuration and the Ω -loop is in the folded, closed conformation (Fig. 8, C and D). In addition, the 103–106 loop is in a similar position as in the ceftazidime-bound structure with the side chain of Asn¹⁰⁴ pointed out of the active site and with elevated B-factors for Val¹⁰³ and Asn¹⁰⁴ (Fig. 6A). Thus, this conformation of the enzyme, and particularly the 103–106 loop, occurs in the absence of ceftazidime, in contrast to the different conformations of the E166A/P167S apo and E166A/P167S/CAZ structures where the presence of ceftazidime is apparently required to produce the conformational change.

The second E166A/P167S/D240G/CAZ structure is superimposable with that of the E166A/P167S/CAZ structure where the peptide bond preceding Ser¹⁶⁷ is in the *trans* configuration, and the Ω -loop is in an unfolded, open conformation to accommodate ceftazidime (Fig. 7E). Because the P167S enzyme exhibits enhanced ceftazidime hydrolysis, these findings suggest that the conformation of the enzyme in the E166A/P167S/D240G/CAZ-2 structure is competent to hydrolyze ceftazidime.

The two structures of E166A/P167S/D240G/CAZ with distinct conformations of the enzyme and ceftazidime suggests there are at least two conformational substates of the P167S/D240G enzyme in the presence of ceftazidime. We suggest that the form with the closed Ω -loop and altered 103–106 loop with Asn¹⁰⁴ pointed out of the active site does not efficiently hydrolyze ceftazidime, whereas the form with the open Ω -loop is catalytically competent.

Molecular dynamics simulations reveal that conformational heterogeneity of the Ω -loop is greater in the single mutants than in the WT or double mutant

To directly probe the conformational heterogeneity of the Ω -loop and acyl-enzyme complex, we conducted molecular dynamics simulations of the acylated forms of WT, D240G, P167S, and P167S/D240G. In addition to providing atomically detailed models of the distribution of structures that CTX-M adopts, the fact that no chemical reactions occur in these sim-




Figure 8. Structures of the active-site region of the CTX-M-14 E166A/P167S and E166A/P167S/D240G enzymes in the apo and compared with the respective ceftazidime acyl-enzyme complexes. A, E166A/P167S apo enzyme structure (PDB code 5VTH) (brown). Oxygen is shown in red, and nitrogen is in blue. B, structural alignment of E166A/P167S apo enzyme structure (brown) with the E166A/P167S/CAZ structure (light blue) (PDB code 5TW6). C, E166A/P167S/D240G apo enzyme structure (yellow). D, structural alignment of E166A/P167S/D240G apo enzyme structure (yellow) with E166A/P167S/D240G/CAZ structure (pink).

ulations allowed us to include Glu¹⁶⁶ and interrogate its interactions with ceftazidime and CTX-M. Simulations of WT were initiated from a crystal structure of the acyl-enzyme complex (PDB code 5U53) (25), and simulations of P167S were initiated based on a previous model of the E166A/P167S/CAZ structure (PDB code 5TW6) (25). Simulations of D240G were initiated from the E166A/D240G/CAZ crystal structure presented in this work. The closed-conformation crystal structure of E166A/P167S/D240G/CAZ-1 was the initial starting structure for simulations of P167S/D240G/CAZ. In all structures, Ala¹⁶⁶ was mutated back to a glutamic acid, and a total of 2.5 μ s of simulation was run for each variant.

The distribution of Ω -loop conformations observed in our simulations suggests a correlation between Ω -loop opening and ceftazidime hydrolysis activity. The WT and P167S/D240G variant with acylated ceftazidime both favor a well-defined closed conformation (Fig. 9). However, we note that the P167S/

D240G variant with acylated ceftazidime sparsely samples open conformations of the Ω -loop, some of which are very similar to the crystallographic structure capturing the open state (Fig. 7, D and E, and Fig. S3). A previous combination of simulations and experiments have also demonstrated that the WT has a sparsely populated state with an open Ω -loop (38). In contrast, the P167S and D240G substitutions dramatically increase the probability of a diversity of open conformations. The conformational heterogeneity of P167S is consistent with the open structure and elevated B-factors observed in the E166A/P167S/CAZ crystal structure (Figs. 6 and 7B). Although D240G also displays substantial conformational heterogeneity, it has a deeper minima for the closed state than P167S, potentially explaining why only the closed state of D240G has been observed crystallographically so far (Fig. 7C).

These simulations suggest that the closed conformation inhibits catalysis by favoring a conformation of Glu¹⁶⁶ that is

Epistasis between resistance mutations in β -lactamase




Figure 9. The conformational heterogeneity of the Ω -loop is greater in the single mutants than in the WT or double mutant. A, joint distributions of two $\text{C}\alpha$ - $\text{C}\alpha$ distances that capture the conformational heterogeneity of the Ω -Loop: (i) Asn¹⁰⁴ to position 167 on one side of the Ω -loop and (ii) Thr¹⁷¹ to position 240 on the other side. Distributions are shown for WT (top left panel), D240G (top right panel), P167S (bottom left panel), and P167S/D240G (bottom right panel). Each point represents a snapshot from the molecular dynamics simulations colored according to its probability based on a 2D histogram. B, cumulative distribution of distances between the $\text{C}\gamma$ atom of Glu¹⁶⁶ and the $\text{N}\delta$ atom of Asn¹⁷⁰ for WT (black), D240G (blue), P167S (red), and P167S/D240G (purple), capturing the loss of interaction between Glu¹⁶⁶ and Asn¹⁷⁰ in the open state. C, distribution of distances between the sidechain $\text{N}\delta$ atom of Asn¹³² and the $\text{C}\gamma$ of Glu¹⁶⁶ for WT (black), D240G (blue), P167S (red), and P167S/D240G (purple), capturing the newly formed interaction between Glu¹⁶⁶ and Asn¹³² in the open state.

incompatible with a deacylation reaction, whereas the open conformation of the Ω -loop allows Glu¹⁶⁶ to adopt a wider range of conformations, at least some of which are compatible

with the requirements for deacylation. Previous work has established that Glu¹⁶⁶ coordinates a water that plays a role in the deacylation reaction (39) and that mutation of Glu¹⁶⁶ traps the acyl intermediate by inhibiting deacylation (29). Examining closed structures preferentially adopted by WT and P167S/D240G reveals that the carboxyl group of Glu¹⁶⁶ tends to hydrogen bond with Asn¹⁷⁰, trapping Glu¹⁶⁶ under the Ω -loop and preventing it from coordinating the water required for deacylation (Figs. 9, B and C, and 10). In the open conformations preferentially sampled by the D240G and P167S variants, the hydrogen bond between Asn¹⁷⁰ and Glu¹⁶⁶ is disrupted. This open conformation is stabilized by a rearrangement of the hydrogen-bonding network in the active site where Asn¹³² hydrogen bonds with Glu¹⁶⁶ (Figs. 9C and 10).

The opening and closing of the Ω -loop is also associated with a rearrangement of ceftazidime in the acyl-enzyme complex (Fig. 10 and Fig. S1). One major feature observed in both crystal structures and simulations is that the aminothiazole ring of ceftazidime is buried under the Ω -loop when it is open (Figs. 7, B and E, and 10). Consistent with the crystal structures of the single-mutant variants, this rearrangement of ceftazidime in the acyl-enzyme complex is facilitated by new interactions with Asn¹⁰⁴ and the β 3 loop. In the D240G and P167S constructs, Ser²³⁷ and Asn¹⁰⁴ form interactions with ceftazidime (Fig. 10 and Figs. S1 and S2). We also note an additional interaction between the imino group of ceftazidime and Ser²³⁷ that is present in the more open, active variants but not the more closed, inactive variants (Fig. S2). These interactions with ceftazidime are rare in the WT and P167S/D240G simulations (Figs. S1 and S2). Furthermore, Asn¹⁰⁴ appears to point outward toward the solvent in the closed configuration (Fig. 10), similar to what is seen in the crystal structure of the closed configuration of the P167S/D240G/CAZ variant (Fig. 7D).

Overall, our simulations suggest that the CTX-M acyl-enzyme complex is in equilibrium between inactive and active conformations and that the P167S and D240G variants have a higher probability of adopting active conformations (Fig. 10). In the inactive conformation the Ω -loop is closed, burying the Asn¹⁷⁰-Glu¹⁶⁶ hydrogen bond under the aminothiazole ring (Fig. 10). Opening of the Ω -loop and rearrangement of ceftazidime via burial of the aminothiazole ring and coordination between the imino group and Asn¹⁰⁴ and the β 3 loop likely transitions CTX-M into a catalytically competent state. These rearrangements of the Ω -loop and ceftazidime allow Glu¹⁶⁶ to coordinate a water molecule that can access the ester bond of the ceftazidime-acyl-enzyme complex, facilitating the deacylation reaction. Taken together, the crystallography and molecular dynamics results indicate that the P167S and D240G substitutions promote an open conformation of the Ω -loop that creates access for ceftazidime and allows Glu¹⁶⁶ to sample conformations consistent with deacylation, whereas the WT and P167S/D240G mutant exhibit a closed Ω -loop conformation that constrains access for ceftazidime and prevents Glu¹⁶⁶ from efficiently coordinating water for deacylation.

Discussion

The CTX-M β -lactamases emerged in the late 1980s and are characterized by their ability to efficiently hydrolyze cepha-




Figure 10. Conformational changes between inactive and active forms of the acyl-enzyme. Representative structures of the CTX-M acyl-enzyme complex with ceftazidime (labeled CAZ, green) highlighting inactive (blue, left panels) and active (orange, right panels) conformations. Conformations of the Ω -loop (top panels) and residues contacting ceftazidime (bottom panels) are shown, with relevant residues labeled. Key hydrogen bond interactions are depicted in dashed lines (black).

losporins, particularly the oxyimino-cephalosporin cefotaxime (20, 21). For example, the catalytic efficiency for cefotaxime hydrolysis by CTX-M enzymes is 1500-fold higher than that exhibited by the common TEM-1 β -lactamase (17). Nevertheless, the related oxyimino-cephalosporin ceftazidime is poorly hydrolyzed by CTX-M enzymes with k_{cat}/K_m values 1000-fold lower than those observed for cefotaxime (17). Natural variants of the TEM-1 enzyme have evolved through mutations that provide increased rates of ceftazidime catalysis. Similarly, the P167S and D240G substitutions have been found in multiple variants of CTX-M enzymes that exhibit increased ceftazidime hydrolysis (21, 26–28, 41). Each of these substitutions results in a 10-fold increased k_{cat}/K_m value for ceftazidime hydrolysis (22, 24). However, variants containing both substitutions have not been observed, despite the prediction that such variants would exhibit increased hydrolysis. Here we have shown that the failure of the double mutant to emerge in natural isolates is due to epistasis resulting from decreased stability and lower bacterial expression levels of the P167S/D240G enzyme, as well as antagonism between the substitutions with respect to catalysis.

The combination of amino acid substitutions that each increase catalytic activity can display simple additivity or cooperativity when introduced together into an enzyme (4). For additive interactions, the fold change of the double mutant is expected to be the product of the fold changes of the single mutants. Such additive combinations indicate that the substitutions have independent effects on catalysis (4). However, not all substitutions act additively. The CTX-M P167S and D240G substitutions are antagonizing in the double mutant (Table 2). This negative cooperativity suggests that the substitutions interact, either directly or indirectly, and that the interaction

has a negative effect on ceftazidime catalysis (4). In the case of the P167S and D240G substitutions, the interaction is not via direct contact, because the α -carbons are located 10.7 Å apart.

X-ray crystallography and molecular dynamics simulations of the P167S, D240G, and P167S/D240G mutants provide a rationale for the increased ceftazidime hydrolysis by the single mutants and the negative cooperativity observed for the double mutant. The acyl-enzyme complex of the E166A/P167S/CAZ X-ray structure shows a *trans* configuration peptide bond preceding residue 167 and an unfolded Ω -loop in an open conformation with the aminothiazole ring of the antibiotic in a buried position. This interaction increases van der Waals contacts and hydrogen bonds between the enzyme and ceftazidime and is consistent with enhanced catalytic efficiency toward ceftazidime. In contrast, the E166A/D240G/CAZ structure revealed a closed conformation. Two structures were obtained for the E166A/P167S/D240G ceftazidime acyl-enzyme, one of which is superimposable with the open Ω -loop structure of E166A/P167S/CAZ and, based on this similarity, is proposed to hydrolyze ceftazidime. The second structure, however, displays a closed Ω -loop and an altered conformation of the 103–106 loop such that the critical Asn¹⁰⁴ residue is turned out of the active site and does not interact with ceftazidime, suggesting reduced ceftazidime catalysis.

Although the E166A/P167S/CAZ and E166A/D240G/CAZ structures suggest that the substitutions act by different mechanisms, 2.5- μ s molecular dynamics simulations of each variant indicate that both the P167S and D240G substitutions promote an open conformation of the Ω -loop to accommodate ceftazidime and that the WT and P167S/D240G enzymes exhibit

Epistasis between resistance mutations in β -lactamase

reduced ceftazidime hydrolysis because open conformations of the Ω -loop are less probable.

The TEM-1 β -lactamase is $\sim 35\%$ identical in amino acid sequence to CTX-M enzymes and efficiently hydrolyzes penicillins and many cephalosporins, but oxyimino-cephalosporins are poor substrates (17). Nevertheless, natural variants of TEM-1 have evolved that exhibit increased catalytic efficiency for cefotaxime and ceftazidime hydrolysis (42, 43). These variants, termed extended-spectrum β -lactamases (ESBLs), contain 1–5 amino acid substitutions, and multiply substituted enzymes are common. Many of the substitutions found in these variants act additively when combined (17). Some combinations of mutations, however, are not additive. A well-studied example is the combination of the R164S and G238S substitutions. The Gly²³⁸ residue is on the $\beta 3$ strand (analogous to Gly²³⁸ in CTX-M-14), and Arg¹⁶⁴ is at the base of the Ω -loop. Each of these substitutions results in increased enzyme activity toward cefotaxime and ceftazidime, yet the double mutant has reduced activity (6, 44). Dellus-Gur *et al.* (6) determined the structure of the TEM-1 G238S and R164S enzymes. The G238S-containing enzyme exhibited two dominant conformations of the G238 loop, whereas the R164S substitution induced an ensemble of conformations of the Ω -loop. The structure of the R164S/G238S double mutant, however, exhibited a wider ensemble of conformations of the Ω -loop than the single mutants (6). Based on these results, it was hypothesized that the entropic cost of the substrate selecting suitable conformations among many alternatives results in the low activity for cefotaxime hydrolysis by the double mutant, accounting for the negative epistasis observed for the combination (6).

In the case of the negative epistasis observed with the P167S and D240G combination in CTX-M β -lactamase, multiple conformations of the enzyme also appear to play a role. Based on our molecular dynamics simulation results, the P167S and D240G substitutions are analogous to the R164S substitution in TEM-1, where the substitutions induce an ensemble of conformations, some of which are predicted to be capable of hydrolyzing ceftazidime. The CTX-M P167S and D240G substitutions antagonize each other in the double mutant, similar to the TEM-1 R164S and G238S substitutions. The mechanism of antagonism, however, is different, with the CTX-M P167S/D240G double mutant showing a reduced probability of sampling multiple conformations of the Ω -loop, whereas the TEM-1 R164S/G238S double mutant Ω -loop samples an excess of conformations (6). Nevertheless, both cases demonstrate the importance of conformational heterogeneity of active-site loops in controlling catalytic activity and evolutionary trajectories.

Several studies have provided evidence that the conformation of the Ω -loop is an important determinant of substrate specificity of class A β -lactamases, particularly with regard to the hydrolysis of oxyimino-cephalosporins. As described above, the TEM ESBL mutation R164S is thought to broaden the specificity of the enzyme by increasing the conformational heterogeneity of the Ω -loop (6). In addition, the structure of an apo enzyme form of a triple mutant of the TEM enzyme containing the substitutions W165Y/E166Y/P167G that hydrolyzes ceftazidime shows the Ω -loop in an unfolded, open con-

formation similar to that observed for the CTX-M E166A/P167S/CAZ and E166A/P167S/D240G/CAZ-2 structures (45). Further, computational studies predict that TEM ESBL substitutions that broaden the specificity of the enzyme to include cefotaxime stabilize conformations of the Ω -loop that facilitate substrate binding (46).

The results also suggest an important role for the active-site 103–106 loop in cefotaxime and ceftazidime hydrolysis. We recently showed that an N106S mutation in the 103–106 loop that is found in CTX-M enzymes from clinical isolates lowers cefotaxime and ceftazidime hydrolysis because of a change in conformation of the loop (36). Asn¹⁰⁶ is at the base of the loop and not in the active site. However, the N106S substitution changes the hydrogen-bonding network connectivity in the loop such that the side chain of Asn¹⁰⁴ rotates out of the active site, thereby eliminating a hydrogen bond with substrate. Further experiments showed that an N104A mutant exhibits 10-fold reduced catalytic efficiency for oxyimino cephalosporin hydrolysis, suggesting that the hydrogen bond is important for catalysis. Thus, the conformation of the 103–106 loop is a determinant of substrate specificity (36). In this study, it was found that the P167S/D240G enzyme, which exhibits reduced ceftazidime hydrolysis, has increased B-factors for the 103–106 loop, suggesting disorder in Asn¹⁰⁴ that is consistent with reduced activity. In addition, in the structure of the E166A/P167S/D240 apo enzyme the B-factors of the 103–106 loop are increased, and in one of the structures of E166A/P167S/D240G in complex with ceftazidime, the side chain of Asn¹⁰⁴ is rotated out of the active site, again consistent with decreased ceftazidime hydrolysis. Thus, although the P167S and D240G substitutions are not in the 103–106 loop, the antagonism between the substitutions is at least partially reflected in changes in the conformation of the loop.

Thermal stability studies of the WT, P167S, D240G, and P167S/D240G enzymes show that the single mutants are less stable than WT, whereas the double mutant is less stable than either single mutant. There is some correlation between stability and protein expression levels in that the P167S/D240G mutant is the least stable and is also expressed at the lowest levels among the mutants. However, also note the P167S mutant is less stable than D240G but is expressed at higher levels, suggesting there are exceptions to the stability/protein expression level correlation. Some recent studies have shown that lower enzyme stability correlates with increased flexibility and increased cephalosporin hydrolysis in β -lactamases (47, 48). Here, we do not observe a correlation between stability and flexibility in that the P167S and D240G mutants readily sample multiple conformations and yet are more stable than P167S/D240G, which samples fewer conformations. Further, we do not observe a correlation between stability and catalytic activity toward ceftazidime because P167S/D240G has low stability but also low activity.

Taken together, the results presented here suggest that active-site loops play an important role in the substrate specificity and evolutionary capacity of β -lactamases. Class A β -lactamases such as TEM and CTX-M can evolve altered substrate specificity by mutations that change the conformation of active-site loops. An active site with flexible loops loosely associ-

ated with a highly ordered, stable scaffold structure has been described as fold polarity, and there is evidence that such an organization facilitates the evolution of new functions because of a tolerance to changes in the loops without drastically destabilizing the enzyme (7). Such an organization is clearly advantageous for antibiotic resistance enzymes such as CTX-M β -lactamases that are under selective pressure for altered substrate specificity.

Experimental procedures

Bacterial strains and plasmids

The CTX-M-14-pTP123 plasmid was used for site-directed mutagenesis, MIC determinations, and immunoblotting. This plasmid was constructed by inserting the *bla*CTX-M-14 gene into the previously described pTP123 plasmid. CTX-M-14-pTP123 has a chloramphenicol (CMP) resistance marker and β -lactamase expression is controlled by the isopropyl- β -D-galactopyranoside (IPTG)-inducible P_{trc} promoter (49). Under conditions without IPTG, protein expression is maintained at a basal level; these were the conditions under which MIC determination and immunoblotting were performed. The *E. coli* strain XL1-Blue {*recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac* [F9 *proAB lacI^qZM15 Tn10* (Tet^r)]} (Stratagene, Inc., La Jolla, CA) was used as the host for the construction of the P167S/D240G CTX-M-14 mutant via site-directed mutagenesis, as well as MIC determination. The *E. coli* strain RB791 (W3110 *lacIqL8*) was used as the host for the determination of protein expression levels of WT CTX-M-14 β -lactamase and its mutants (50). For protein purification, WT CTX-M-14 and the mutants were expressed in the pET28a plasmid using the protocol outlined by Patel *et al.* (24). CTX-M-14 and mutants in the pET28a plasmid were expressed in BL21(DE3) [*fhuA2 (lon) ompT gal* (λ DE3) (*dcm*) Δ *hsdS* λ DE3 = λ *SbamHIo* Δ *EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21* Δ *nin5*)] (51).

Site-directed mutagenesis

The CTX-M-14 P167S/D240G mutant was constructed using the D240G mutant in pTP123 as template for QuikChange mutagenesis using 1 unit of Phusion DNA polymerase (New England Biolabs, Ipswich, MA) and 0.4 μ M P167S primer (5'-CTGGATCGCACTGAAAGCACGCTG-AATACCGCC-3') (24). Primers were obtained from Integrated DNA Technologies (Coralville, IA). Thermocycler products were digested with DpnI (New England Biolabs) and transformed into electrocompetent *E. coli* XL1-Blue cells and selected on LB agar supplemented with 12.5 μ g/ml chloramphenicol. The DNA sequence of the resulting mutant was confirmed by DNA sequencing (Genewiz, Plainfield, NJ). The E166A/P167S/D240G mutant was constructed by QuikChange mutagenesis with a primer encoding the E166A/P167S mutations (5'-GATCGCACTGCTC-CTACGCTGAAT-3') using CTX-M-14 P167S/D240G pTP123 as template and confirmed using DNA sequencing.

Minimum inhibitory concentration determinations

MICs for cephalothin were determined by Etest strip (BioMérieux, Marcy-l'Étoile, France). This was performed by grow-

ing a single colony of *E. coli* XL1-Blue harboring the pTP123 plasmid with either WT, mutant CTX-M-14, or empty vector overnight in LB supplemented with 12.5 μ g/ml CMP in a shaking incubator at 37 °C. The overnight culture was diluted 10² and spread onto LB agar containing CMP, an Etest strip was placed on the agar, and the MIC was determined based on the zone of inhibition.

MIC determinations for cefotaxime were performed by broth dilution. Again, a single colony of *E. coli* XL1-Blue harboring pTP123 with WT or mutant CTX-M-14 or empty vector was grown overnight in LB with CMP in a shaking incubator at 37 °C. The cultures were diluted 10⁴, and 100 μ l of culture was used to inoculate 2 ml of LB supplemented with increasing concentrations of cefotaxime in 14-ml test tubes. Concentrations of cefotaxime (in μ g/ml) used for WT and D240G were 0, 1, 1.5, 2, and 3. The concentrations used for the P167S and P167S/D240G mutants were 0, 0.1875, 0.25, 0.375, and 0.5, and for pTP123 empty vector control, the concentrations were 0, 0.03, 0.045, and 0.06. The cultures were incubated with shaking for 18 h at 37 °C. The concentration at which no visible growth was observed was reported as the MIC.

MIC determinations for ceftazidime were performed by broth dilution, with a single colony of *E. coli* XL1-Blue harboring pTP123 with WT or mutant CTX-M-14 or empty vector being grown overnight in LB with CMP, as above. Saturated cultures were diluted 10⁴, and 25 μ l was used to inoculate 500 μ l of LB supplemented with increasing concentrations of ceftazidime in a deep-well 96-well plate. Concentrations of ceftazidime (in μ g/ml) used for WT, D240G, P167S/D240G, and pTP123 empty vector were 0, 0.12, 0.19, 0.25, 0.38, 0.5, 0.75, 1, 1.5, 2, 3, and 4; for P167S, the concentrations were 0, 0.38, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, and 12. The 96-well plate was covered with a sterile, breathable seal (Excel Scientific, Victorville, CA) and incubated shaking at 37 °C for 18 h. The concentration at which no growth was observed ($A_{600} < 0.1$) was recorded as the MIC.

Immunoblotting

To determine the effects of the P167S/D240G mutation on steady-state protein expression, single colonies of *E. coli* RB791 harboring pTP123 or the recombinant pTP123 encoding WT or mutant CTX-M-14 β -lactamase were incubated overnight with shaking in 2 \times YT medium supplemented with 12.5 μ g/ml CMP at 37 °C. A total of 10 ml of 2 \times YT medium with CMP was inoculated with 100 μ l of overnight culture and incubated at 37 °C while shaking until the A_{600} reached between 0.9. The cells were pelleted, and the periplasmic proteins were extracted by osmotic shock as described previously (36). The proteins were fractionated by SDS-PAGE and transferred onto a nitrocellulose membrane (GE Healthcare). The membrane was probed with a rabbit serum raised against CTX-M-14 protein and a rabbit serum raised against maltose-binding protein (MBP) (a gift from Dr. Anna Konovalova, University of Texas Health Science Center at Houston), which functions as a loading control. Then the membrane was probed with a donkey anti-rabbit secondary antibody conjugated with horseradish peroxidase (GE Healthcare). After development of the immunoblot with the SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific), the hybridization signals of

Epistasis between resistance mutations in β -lactamase

CTX-M-14 β -lactamase and MBP were quantified by densitometry using ImageJ software (National Institutes of Health). The signal for WT and mutant CTX-M-14 β -lactamase was normalized to that for MBP.

Protein purification

WT CTX-M-14 β -lactamase and the P167S/D240G mutant were expressed from a pET28a vector in *E. coli* BL21(DE3) cells. Proteins expressed in this plasmid have an N-terminal His tag with a TEV protease cleavage site. *E. coli* BL21(DE3) cells harboring the CTX-M-14 plasmid were used to inoculate LB supplemented with 25 μ g/ml kanamycin and incubated at 37 °C in a shaking incubator until the A_{600} reached \sim 0.9, at which time IPTG was added to yield a final concentration of 0.2 mM to induce protein expression. The culture was then grown for 20 h at 23 °C in a shaking incubator. The culture was centrifuged at 8000 rpm at 4 °C, and the pellet was stored overnight at -80 °C. The pellet was then thawed on ice and resuspended in 30 ml of lysis buffer (20 mM HEPES, pH 7.4, 300 mM NaCl, 20 mM imidazole). The cells were lysed using a French Press at 1250 p.s.i. and a probe sonicator, followed by centrifugation for 50 min at 10,000 rpm and filtration of the supernatant with a 0.45- μ m filter (EMD Millipore, Billerica, MA). Filtered lysate was then bound to a HisTrap FF column (GE Healthcare) equilibrated with the lysis buffer. The CTX-M-14 enzyme was eluted using 20–500 mM imidazole gradient in the lysis buffer. Pure fractions containing His-CTX-M-14 protein were pooled, concentrated, and buffer-exchanged to the lysis buffer using 10-kDa molecular mass cutoff centrifugal filters (EMD Millipore). 0.25 mg of TEV protease was added to the His-tagged enzyme and incubated overnight at 4 °C. TEV protease and uncleaved His-CTX-M-14 protein were removed by incubation with nickel-Sephacrose Hi-Performance beads (GE Healthcare). CTX-M-14 proteins were further purified by gel-filtration chromatography with Superdex 75 Increase column using (20 mM HEPES, pH 7.4, 150 mM NaCl) as running buffer. The fractions corresponding to monomer of CTX-M-14 WT or P167S/D240G mutant protein were pooled and concentrated with 10-kDa molecular mass cutoff centrifugal filters. The purity of purified proteins was $>95\%$ determined by SDS-PAGE. Their concentrations were determined by measuring the absorbance at 280 nm with DU800 spectrophotometer (Beckman Coulter) and using an extinction coefficient of 23,950 $M^{-1} cm^{-1}$.

Determination of thermal stabilities

Thermal stabilities of the WT and mutant enzymes were determined as previously described (24). In short, the fraction of folded protein was measured with a spectropolarimeter at 222 nm, while the temperature was increased from 30 to 70 °C at a rate of 0.01 °C/s. The melting temperature (T_m), the temperature midpoint of protein unfolding, was determined by fitting the data to a single Boltzmann two-state model using GraphPad Prism 6 (San Diego, CA) (33).

Steady-state enzyme kinetic parameters

Michaelis–Menten steady-state kinetic parameters were measured as previously described (24, 52). The kinetic parameters for CTX-M-14 P167S and D240G are from Patel *et al.* (24).

Antibiotic hydrolysis was measured at 30 °C in 50 mM phosphate buffer (pH 7.0) containing 1 μ g/ml BSA. BSA was added to stabilize β -lactamase when it is diluted to low concentration for kinetic assays. Cephalothin, cefotaxime, and ceftazidime hydrolysis were measured at 262, 264, and 260 nm, respectively (24). K_m and k_{cat} were determined by fitting the initial velocities of increasing substrate concentrations to the Michaelis–Menten equation using GraphPad Prism 6. For ceftazidime, which has a $K_m > 500$ μ M, k_{cat}/K_m was estimated using the equation, $v = k_{cat}/K_m[E][S]$, where $[S] \ll K_m$. All measurements were performed at least in duplicate. k_{cat} and K_m values from each run were averaged, and the standard deviations reported are the sums of the percent standard deviations of k_{cat} and K_m (24).

Protein crystallization and structure determination

Crystallization conditions were screened based on previously solved crystal structures for CTX-M-14. Purified P167S/D240G enzyme in 50 mM phosphate buffer, pH 7.0, was concentrated to 40 mg/ml, and protein was mixed with mother liquor 1:1 in a 200-nl drop and grown by hanging-drop vapor diffusion. Diffraction-quality crystals were obtained in 0.1 M MIB buffer (malonic acid, imidazole, and boric acid buffer), pH 4.0, 25% (w/v) PEG 1500, and were harvested and cryoprotected in 25% glycerol:75% mother liquor. The crystals were plunged in liquid nitrogen and sent to Beamline 5.0.2 at the Advanced Light Source (Berkeley, CA) for data collection. Because the first data set appeared to show high twinning, a second data set was collected on the same crystal. This data set was processed at 1.5 Å in the space group $P4_12_12$ using HKL200 and the Phaser program from the CCP4 suite was used for molecular replacement. CTX-M-14 (PDB code 1YLT) was used as a phasing model (22). Refinement was performed using REFMAC5 and phenix.refine, as part of the Phenix program suite (53). The model was built manually using COOT (54).

E166A/P167S/D240G was crystallized by concentrating the protein in 50 mM phosphate buffer, pH 7.0, to 40 mg/ml and mixing with mother liquor 1:1 in a 200-nl drop and grown by hanging-drop vapor diffusion. Crystals from the condition containing 0.1 M PCB buffer, pH 6, 25% (w/v) PEG 1500 were soaked for 24 h in 25 mM ceftazidime, 20% glycerol:80% mother liquor. Structure determination indicated an acyl-enzyme complex with ceftazidime. Crystals grown in the condition containing 0.2 M CaCl₂, 0.1 M sodium acetate, pH 5, 20% (w/v) PEG 6000 were also soaked for 24 h in 25 mM ceftazidime, 20% glycerol:80% mother liquor but were not in complex with ceftazidime, resulting in the apoenzyme. The data were collected on Beamline ALS 501 and was processed as described above. The E166A/P167S/D240G enzyme was also crystallized by concentrating the protein in 50 mM phosphate buffer, pH 7.0, to 36 mg/ml, mixing with mother liquor 1:1 in a 200-nl drop, and grown by hanging-drop vapor diffusion. Crystals obtained in the condition 0.1 M MMT (1:2:2 ratio of DL-malic acid:MES:Tris base), pH 6.0, 25% (w/v) PEG 1500 were soaked for 24 h in 25 mM ceftazidime, 25% glycerol:75% mother liquor. The data were collected on Beamline ALS 821. Structure determination revealed an acyl-enzyme complex with ceftazidime with the Ω -loop in an open conformation.

E166A/D240G was crystallized by concentrating the protein in 50 mM phosphate buffer, pH 7.0, to 36 mg/ml and mixing with mother liquor 1:1 in a 200-nl drop and grown by hanging-drop vapor diffusion. Crystals grown in 0.1 M Tris-HCl, pH 8.5, 25% (w/v) PEG 3000 were soaked for 24 h in 25 mM ceftazidime, 25% glycerol:75% mother liquor. The data were collected on Beamline ALS 822. However, structure determination revealed this to be the apo enzyme. Crystals grown in the condition 0.2 M NaCl, 0.1 M Tris, pH 8.0, 20% (w/v) PEG 6000 were soaked for 24 h in 15 mM ceftazidime, 25% glycerol:75% mother liquor, the data were collected on Beamline ALS 822, and structure determination revealed an acyl-enzyme complex with ceftazidime. The data set was processed as described above for the P167S/D240G enzyme. X-ray crystallography statistics are listed in Table S1.

Molecular dynamics simulations

As described previously (46), simulations were run at 300 K with the GROMACS software package (46, 55–57) using the Amber03 force field (58) and TIP3P explicit solvent (59). Mutations were introduced in PyMOL (60), and parameters for the acyl group were generated with the generalized amber force field (40, 61, 37). A total of 2.5 μ s of simulation were run for each variant.

Author contributions—C. A. B., B. V. V. P., G. R. B., and T. P. conceptualization; C. A. B., L.H., Z.S., M.P.P., S.S., J.R.P., and B.S. investigation; C. A. B., L.H., Z.S., M.P.P., S.S., J.R.P., and B.S. methodology; C. A. B. and T. P. writing-original draft; C. A. B., L.H., Z.S., M.P.P., S.S., J.R.P., B.S., B. V. V. P., G. R. B., and T. P. writing-review and editing; L.H., Z.S., S.S., J.R.P., B.S., B. V. V. P., G. R. B., and T. P. formal analysis; Z.S. data curation; S.S. visualization; B. V. V. P., G. R. B., and T. P. supervision; B. V. V. P., G. R. B., and T. P. funding acquisition.

Acknowledgments—We thank Hiram Gilbert for discussions and comments on the manuscript. The ALS-ENABLE Beamlines are supported in part by National Institutes of Health, NIGMS Grant P30 GM124169-01. The Advanced Light Source is a Department of Energy Office of Science User Facility under Contract DE-AC02-05CH11231.

References

- Knowles, J. R. (1991) Enzyme catalysis: not different, just better. *Nature* **350**, 121–124 [CrossRef Medline](#)
- Breen, M. S., Kemena, C., Vlasov, P. K., Notredame, C., and Kondrashov, F. A. (2012) Epistasis as the primary factor in molecular evolution. *Nature* **490**, 535–538 [CrossRef Medline](#)
- de Visser, J. A., and Krug, J. (2014) Empirical fitness landscapes and the predictability of evolution. *Nat. Rev. Genet.* **15**, 480–490 [CrossRef Medline](#)
- Wells, J. A. (1990) Additivity of mutational effects in proteins. *Biochemistry* **29**, 8509–8517 [CrossRef Medline](#)
- Weinreich, D. M., Delaney, N. F., Depristo, M. A., and Hartl, D. L. (2006) Darwinian evolution can follow only very few mutational paths to fitter proteins. *Science* **312**, 111–114 [CrossRef Medline](#)
- Dellus-Gur, E., Elias, M., Caselli, E., Prati, F., Salverda, M. L., de Visser, J. A., Fraser, J. S., and Tawfik, D. S. (2015) Negative epistasis and evolvability in TEM-1 β -lactamase: the thin line between an enzyme's conformational freedom and disorder. *J. Mol. Biol.* **427**, 2396–2409 [CrossRef Medline](#)
- Dellus-Gur, E., Toth-Petroczy, A., Elias, M., and Tawfik, D. S. (2013) What makes a protein fold amenable to functional innovation? Fold polarity and stability trade-offs. *J. Mol. Biol.* **425**, 2609–2621 [CrossRef Medline](#)
- Doucet, N., Watt, E. D., and Loria, J. P. (2009) The flexibility of a distant loop modulates active site motion and product release in ribonuclease A. *Biochemistry* **48**, 7160–7168 [CrossRef Medline](#)
- Whittier, S. K., Hengge, A. C., and Loria, J. P. (2013) Conformational motions regulate phosphoryl transfer in related protein tyrosine phosphatases. *Science* **341**, 899–903 [CrossRef Medline](#)
- James, L. C., and Tawfik, D. S. (2003) Conformational diversity and protein evolution: a 60-year-old hypothesis revisited. *Trends Biochem. Sci.* **28**, 361–368 [CrossRef Medline](#)
- Tokuriki, N., and Tawfik, D. S. (2009) Protein dynamism and evolvability. *Science* **324**, 203–207 [CrossRef Medline](#)
- Petrović, D., Risso, V. A., Kamerlin, S. C. L., and Sanchez-Ruiz, J. M. (2018) Conformational dynamics and enzyme evolution. *J. R. Soc. Interface* **15**, 20180330 [CrossRef Medline](#)
- Livermore, D. M., and Woodford, N. (2006) The β -lactamase threat in *Enterobacteriaceae*, *Pseudomonas*, and *Acinetobacter*. *Trends Microbiol.* **14**, 413–420 [CrossRef Medline](#)
- Fisher, J. F., Meroueh, S. O., and Mobashery, S. (2005) Bacterial resistance to β -lactam antibiotics: compelling opportunism, compelling opportunity. *Chem. Rev.* **105**, 395–424 [CrossRef Medline](#)
- Ambler, R. P., Coulson, A. F., Frère, J.-M., Ghuysen, J.-M., Joris, B., Forsman, M., Levesque, R. C., Tiraby, G., and Waley, S. G. (1991) A standard numbering scheme for the class A β -lactamases. *Biochem. J.* **276**, 269–270 [CrossRef Medline](#)
- Bush, K., and Fisher, J. F. (2011) Epidemiological expansion, structural studies, and clinical challenges of new β -lactamases from Gram-negative bacteria. *Annu. Rev. Microbiol.* **65**, 455–478 [CrossRef Medline](#)
- Palzkill, T. (2018) Structural and mechanistic basis for extended-spectrum drug resistance mutations in altering the specificity of TEM, CTX-M, and KPC β -lactamases. *Front. Mol. Biosci.* **5**, 16 [CrossRef Medline](#)
- Fisher, J. F., and Mobashery, S. (2009) Three decades of the class A β -lactamase acyl-enzyme. *Curr. Protein Pept. Sci.* **10**, 401–407 [CrossRef Medline](#)
- Galleni, M., and Frère, J.-M. (2007) Kinetics of β -lactamases and penicillin-binding proteins. In *Enzyme-Mediated Resistance to Antibiotics: Mechanisms, Dissemination, and Prospects for Inhibition* (Bonomo, R. A., and Tolmasky, M. E., eds) pp. 67–79, ASM Press, Washington, D.C.
- Bonnet, R. (2004) Growing group of extended-spectrum β -lactamases: the CTX-M enzymes. *Antimicrob. Agents Chemother.* **48**, 1–14 [CrossRef Medline](#)
- D'Andrea, M. M., Arena, F., Pallecchi, L., and Rossolini, G. M. (2013) CTX-M-type β -lactamases: a successful story of antibiotic resistance. *Int. J. Med. Microbiol.* **303**, 305–317 [CrossRef Medline](#)
- Chen, Y., Delmas, J., Sirot, J., Shoichet, B., and Bonnet, R. (2005) Atomic resolution structures of CTX-M β -lactamases: extended spectrum activities from increased mobility and decreased stability. *J. Mol. Biol.* **348**, 349–362 [CrossRef Medline](#)
- Adamski, C. J., Cardenas, A. M., Brown, N. G., Horton, L. B., Sankaran, B., Prasad, B. V., Gilbert, H. F., and Palzkill, T. (2015) Molecular basis for the catalytic specificity of the CTX-M extended spectrum β -lactamases. *Biochemistry* **54**, 447–457 [CrossRef Medline](#)
- Patel, M. P., Fryszczyn, B. G., and Palzkill, T. (2015) Characterization of the global stabilizing substitution A77V and its role in the evolution of CTX-M β -lactamases. *Antimicrob. Agents Chemother.* **59**, 6741–6748 [CrossRef Medline](#)
- Patel, M. P., Hu, L., Stojanoski, V., Sankaran, B., Prasad, B. V. V., and Palzkill, T. (2017) The drug-resistant variant P167S expands the substrate profile of CTX-M β -lactamases for oxyimino-cephalosporin antibiotics by enlarging the active site upon acylation. *Biochemistry* **56**, 3443–3453 [CrossRef Medline](#)
- Bonnet, R., Recule, C., Baraduc, R., Chanal, C., Sirot, D., De Champs, C., and Sirot, J. (2003) Effect of D240G substitution in a novel ESBL CTX-M-27. *J. Antimicrob. Chemother.* **52**, 29–35 [CrossRef Medline](#)

Epistasis between resistance mutations in β -lactamase

27. Kimura, S., Ishiguro, M., Ishii, Y., Alba, J., and Yamaguchi, K. (2004) Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis. *Antimicrob. Agents Chemother.* **48**, 1454–1460 [CrossRef Medline](#)
28. Cantón, R., González-Alba, J. M., and Galán, J. C. (2012) CTX-M enzymes: origin and diffusion. *Front. Microbiol.* **3**, 110 [Medline](#)
29. Strynadka, N. C., Adachi, H., Jensen, S. E., Johns, K., Sielecki, A., Betzel, C., Sutoh, K., and James, M. N. (1992) Molecular structure of the acyl-enzyme intermediate in β -lactam hydrolysis at 1.7 Å resolution. *Nature* **359**, 700–705 [CrossRef Medline](#)
30. Novais, A., Cantón, R., Coque, T. M., Moya, A., Baquero, F., and Galán, J. C. (2008) Mutational events in cefotaximase extended-spectrum β -lactamases for the CTX-M-1 cluster involved in ceftazidime resistance. *Antimicrob. Agents Chemother.* **52**, 2377–2382 [CrossRef Medline](#)
31. Ishii, Y., Galleni, M., Ma, L., Frère, J. M., and Yamaguchi, K. (2007) Biochemical characterisation of the CTX-M-14 β -lactamase. *Int. J. Antimicrob. Agents* **29**, 159–164 [CrossRef Medline](#)
32. Huang, W., and Palzkill, T. (1997) A natural polymorphism in β -lactamase is a global suppressor. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 8801–8806 [CrossRef Medline](#)
33. Brown, N. G., Pennington, J. M., Huang, W., Ayvaz, T., and Palzkill, T. (2010) Multiple global suppressors of protein stability defects facilitate the evolution of extended-spectrum TEM β -lactamases. *J. Mol. Biol.* **404**, 832–846 [CrossRef Medline](#)
34. Mayer, S., Rüdiger, S., Ang, H. C., Joerger, A. C., and Fersht, A. R. (2007) Correlation of levels of folded recombinant p53 in *Escherichia coli* with thermodynamic stability *in vitro*. *J. Mol. Biol.* **372**, 268–276 [CrossRef Medline](#)
35. Yuan, Z., Bailey, T. L., and Teasdale, R. D. (2005) Prediction of protein B-factor profiles. *Proteins* **58**, 905–912 [CrossRef Medline](#)
36. Patel, M. P., Hu, L., Brown, C. A., Sun, Z., Adamski, C. J., Stojanoski, V., Sankaran, B., Prasad, B. V. V., and Palzkill, T. (2018) Synergistic effects of functionally distinct substitutions in β -lactamase variants shed light on the evolution of bacterial drug resistance. *J. Biol. Chem.* **293**, 17971–17984 [CrossRef Medline](#)
37. Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., and Case, D. A. (2004) Development and testing of a general amber force field. *J. Comput. Chem.* **25**, 1157–1174 [CrossRef Medline](#)
38. Porter, J. R., Moeder, K. E., Sibbald, C. A., Zimmerman, M. I., Hart, K. M., Greenberg, M. J., and Bowman, G. R. (2019) Cooperative changes in solvent exposure identify cryptic pockets, switches, and allosteric coupling. *Biophys. J.* **116**, 818–830 [CrossRef Medline](#)
39. Chen, Y., Bonnet, R., and Shoichet, B. K. (2007) The acylation mechanism of CTX-M β -lactamase at 0.88 Å resolution. *J. Am. Chem. Soc.* **129**, 5378–5380 [CrossRef Medline](#)
40. Sousa da Silva, A. W., and Vranken, W. F. (2012) ACPYPE: AnteChamber PYthon Parser interface. *BMC Res. Notes.* **5**, 367 [CrossRef Medline](#)
41. Cartelle, M., del Mar Tomas, M., Molina, F., Moure, R., Villanueva, R., and Bou, G. (2004) High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution. *Antimicrob. Agents Chemother.* **48**, 2308–2313 [CrossRef Medline](#)
42. Petrosino, J., Cantu, C., 3rd, and Palzkill, T. (1998) β -Lactamases: protein evolution in real time. *Trends Microbiol.* **6**, 323–327 [CrossRef Medline](#)
43. Salverda, M. L., de Visser, J. A., and Barlow, M. (2010) Natural evolution of TEM-1 β -lactamase: experimental reconstruction and clinical relevance. *FEMS Microbiol. Rev.* **34**, 1015–1036 [CrossRef Medline](#)
44. Giakkoupi, P., Tzelepi, E., Tassios, P. T., Legakis, N. J., and Tzouveleki, L. S. (2000) Detrimental effect of the combination of R164S with G238S in TEM-1 β -lactamase on the extended-spectrum activity conferred by each single mutation. *J. Antimicrob. Chemother.* **45**, 101–104 [CrossRef](#)
45. Stojanoski, V., Chow, D.-C., Hu, L., Sankaran, B., Gilbert, H. F., Prasad, B. V., and Palzkill, T. (2015) A triple mutant in the w-loop of TEM-1 β -lactamase changes the substrate profile via a large conformational change and an altered general base for catalysis. *J. Biol. Chem.* **290**, 10382–10394 [CrossRef Medline](#)
46. Hart, K. M., Ho, C. M., Dutta, S., Gross, M. L., and Bowman, G. R. (2016) Modelling proteins' hidden conformations to predict antibiotic resistance. *Nat. Commun.* **7**, 12965 [CrossRef Medline](#)
47. Fröhlich, C., Sørum, V., Thomassen, A. M., Johnsen, P. J., Leiros, H. S., and Samuelsen, Ø. (2019) OXA-48-mediated ceftazidime-avibactam resistance is associated with evolutionary trade-offs. *mSphere* **4**, e00024-19 [Medline](#)
48. Barnes, M. D., Taracila, M. A., Rutter, J. D., Bethel, C. R., Galdadas, I., Hujer, A. M., Caselli, E., Prati, F., Dekker, J. P., Papp-Wallace, K. M., Haider, S., and Bonomo, R. A. (2018) Deciphering the evolution of cephalosporin resistance to ceftolozane-tazobactam in *Pseudomonas aeruginosa*. *mBio* **9**, e02085-18 [Medline](#)
49. Petrosino, J., Rudgers, G., Gilbert, H., and Palzkill, T. (1999) Contributions of aspartate 49 and phenylalanine 142 residues of a tight binding inhibitory protein of β -lactamases. *J. Biol. Chem.* **274**, 2394–2400 [CrossRef Medline](#)
50. Amann, E., Brosius, J., and Ptashne, M. (1983) Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in *Escherichia coli*. *Gene* **25**, 167–178 [CrossRef Medline](#)
51. Studier, F. W., and Moffatt, B. A. (1986) Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. *J. Mol. Biol.* **189**, 113–130 [CrossRef Medline](#)
52. Marciano, D. C., Pennington, J. M., Wang, X., Wang, J., Chen, Y., Thomas, V. L., Shoichet, B. K., and Palzkill, T. (2008) Genetic and structural characterization of an L201P global suppressor substitution in TEM-1 β -lactamase. *J. Mol. Biol.* **384**, 151–164 [CrossRef Medline](#)
53. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 213–221 [CrossRef Medline](#)
54. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501 [CrossRef Medline](#)
55. Berendsen, H. J. C., Van Der Spoel, D., and van Drunen, R. (1995) A message-passing parallel molecular dynamics implementation. *Comput. Physics Commun.* **91**, 43–56 [CrossRef](#)
56. Abraham, M. J., Murtola, T., Schulz, R., Pall, S., Smith, J. C., Hess, B., and Lindahl, E. (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX* **1–2**, 19–25 [CrossRef](#)
57. Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., and Berendsen, H. J. (2005) GROMACS: fast, flexible, and free. *J. Comput. Chem.* **26**, 1701–1718 [CrossRef Medline](#)
58. Duan, Y., Wu, C., Chowdhury, S., Lee, M. C., Xiong, G., Zhang, W., Yang, R., Cieplak, P., Luo, R., Lee, T., Caldwell, J., Wang, J., and Kollman, P. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. *J. Comput. Chem.* **24**, 1999–2012 [CrossRef Medline](#)
59. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983) Comparison of simple potential functions for simulating liquid water. *J. Chem. Phys.* **79**, 926–935 [CrossRef](#)
60. DeLano, W. L. (2002) The PyMOL Molecular Graphics System, Schrodinger, LLC, New York
61. Wang, J., Wang, W., Kollman, P. A., and Case, D. A. (2006) Automatic atom type and bond type perception in molecular mechanical calculations. *J. Mol. Graph. Model.* **25**, 247–260 [CrossRef Medline](#)